Literature DB >> 8875280

Quantitation of HCV viraemia by branched DNA signal amplification in patients treated with alpha-interferon--a longitudinal study.

R Iuliano1, A M Pizzigallo, A Alecci, L Barsanti, R Trovato, G Forastieri, S Lico, C Palmieri, M Brizzi, N Marino, L Mecocci, F Mazzotta, L Ceccherini-Nelli.   

Abstract

Using bDNA, the plasma viral load trend of HCV-infected patients undergoing IFN therapy was analyzed. Nine patients were enrolled, each assigned to one of three groups, based on IFN response as determined by ALT and AST level trend. HCV was genotyped using DEIA. Each patient's clinical stage was determined by liver biopsy analysis. In nonresponding patients elevated viral loads and biochemical parameters were observed. These values were not influenced by IFN treatment. In relapsed patients the cessation of IFN treatment increased viral load; this was associated with a rise in ALT and AST values. In responders ALT and AST levels remained normal; viral load was low. Patients with elevated HCV viral load showed a worsening in their liver histology during the follow-up period. These results confirm that plasma viral load is a good marker of biochemical change and disease progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875280     DOI: 10.1007/bf01743362

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

3.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study.

Authors:  S Brillanti; J A Garson; P W Tuke; C Ring; M Briggs; C Masci; M Miglioli; L Barbara; R S Tedder
Journal:  J Med Virol       Date:  1991-06       Impact factor: 2.327

6.  Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus.

Authors:  H T Cuypers; D Bresters; I N Winkel; H W Reesink; A J Weiner; M Houghton; C L van der Poel; P N Lelie
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

7.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

Authors:  J Y Lau; G L Davis; J Kniffen; K P Qian; M S Urdea; C S Chan; M Mizokami; P D Neuwald; J C Wilber
Journal:  Lancet       Date:  1993-06-12       Impact factor: 79.321

8.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

9.  Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participating in a controlled interferon trial.

Authors:  D Bresters; H T Cuypers; H W Reesink; E P Mauser-Bunschoten; H M van den Berg; W P Schaasberg; J C Wilber; M S Urdea; P Neuwald; P N Lelie
Journal:  J Med Virol       Date:  1994-07       Impact factor: 2.327

10.  Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy.

Authors:  M Shindo; K Arai; Y Sokawa; T Okuno
Journal:  Ann Intern Med       Date:  1995-04-15       Impact factor: 25.391

View more
  2 in total

1.  Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels.

Authors:  M Beld; M Penning; M McMorrow; J Gorgels; A van den Hoek; J Goudsmit
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

Review 2.  Lipid peroxidation products and antioxidants in human disease.

Authors:  F J Romero; F Bosch-Morell; M J Romero; E J Jareño; B Romero; N Marín; J Romá
Journal:  Environ Health Perspect       Date:  1998-10       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.